Matt Miksic
Stock Analyst at Barclays
(3.71)
# 770
Out of 5,008 analysts
296
Total ratings
59.83%
Success rate
3.91%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Overweight | $133 → $136 | $95.90 | +41.81% | 19 | Oct 2, 2025 | |
| SENS Senseonics Holdings | Initiates: Overweight | $1.5 | $0.47 | +219.56% | 1 | Aug 27, 2025 | |
| HUMA Humacyte | Initiates: Overweight | $3.5 | $1.65 | +112.77% | 1 | Aug 27, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $55 → $58 | $52.15 | +11.22% | 8 | Aug 21, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $266 → $300 | $313.45 | -4.29% | 9 | Aug 21, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $53 → $51 | $14.52 | +251.24% | 7 | Aug 8, 2025 | |
| BAX Baxter International | Maintains: Overweight | $41 → $36 | $22.90 | +57.21% | 22 | Aug 4, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $21 → $22 | $13.45 | +63.57% | 3 | Aug 4, 2025 | |
| INMD InMode | Maintains: Overweight | $24 → $21 | $15.03 | +39.72% | 14 | Jul 30, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $93 → $98 | $66.03 | +48.42% | 7 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $95 | $76.72 | +23.83% | 29 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $9 → $19 | $18.93 | +0.37% | 8 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $188.89 | -6.82% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $19 → $16 | $14.66 | +9.14% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $192.53 | +25.18% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $2.73 | +339.56% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $440.94 | +44.01% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $133.02 | +19.53% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $59.31 | +73.66% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $99.06 | +13.06% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $369.24 | +19.98% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.37 | +403.43% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $98.33 | +10.85% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $75.37 | +27.37% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $64.88 | +54.13% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $130.47 | +220.38% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.08 | +74.13% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.33 | +443.39% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $6.53 | +7,250.69% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $14.40 | +504.17% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.13 | +505.33% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.26 | +23.97% | 1 | Dec 12, 2016 |
Boston Scientific
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $95.90
Upside: +41.81%
Senseonics Holdings
Aug 27, 2025
Initiates: Overweight
Price Target: $1.5
Current: $0.47
Upside: +219.56%
Humacyte
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.65
Upside: +112.77%
LivaNova
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $52.15
Upside: +11.22%
Insulet
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $313.45
Upside: -4.29%
Tandem Diabetes Care
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $14.52
Upside: +251.24%
Baxter International
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $22.90
Upside: +57.21%
Alphatec Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $13.45
Upside: +63.57%
InMode
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $15.03
Upside: +39.72%
DexCom
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $66.03
Upside: +48.42%
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $76.72
Upside: +23.83%
Jul 22, 2025
Upgrades: Equal-Weight
Price Target: $9 → $19
Current: $18.93
Upside: +0.37%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $188.89
Upside: -6.82%
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $14.66
Upside: +9.14%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $192.53
Upside: +25.18%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.73
Upside: +339.56%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $440.94
Upside: +44.01%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $133.02
Upside: +19.53%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $59.31
Upside: +73.66%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $99.06
Upside: +13.06%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $369.24
Upside: +19.98%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.37
Upside: +403.43%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $98.33
Upside: +10.85%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $75.37
Upside: +27.37%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $64.88
Upside: +54.13%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $130.47
Upside: +220.38%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.08
Upside: +74.13%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.33
Upside: +443.39%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $6.53
Upside: +7,250.69%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $14.40
Upside: +504.17%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.13
Upside: +505.33%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.26
Upside: +23.97%